Member Info for Wiggly

The market is still fast asleep

Avacta owns the global rights to a platform technology fully proven to deliver 100x more war head to Tumor vs Plasma.

Avacta has also now been able to attach 8 new war heads to the pre|CISION substrate with plans to release the pipeline during h2.

With major non dilutive funds incoming imminently (DX divestment + LD) the market has presented a once in a lifetime opportunity!

For those lucky enough to be able to accumulate sub-45, this will be the easiest 4 bags+ you ever make.

Can CC and SC sell the preCISION platform for a pitiful GBP650m within 12 months? Absolutely.

Add exciting Efficacy data from the 2W and we can begin to dream of multiples of GBP650m.

For those lucky enough to be able to accumulate sub-45, this will be the easiest 4 bags+ you ever make.

Can CC and SC sell the preCISION platform for a pitiful GBP650m within 12 months? Absolutely.

Add Efficacy on from 2W

Should never have dropped to 50p (placing) never mind 40p (

Much higher than 48p over coming weeks.

4 fold higher at least

CFO and David Wilson must also go.

Hence why AS and EF have done.

Gbp 36m

Quick sale gbp 30m.

To give some perspective, check out the data from this trial. Note there was ZERO % Complete Response.

Outcome for Advanced or Metastatic Soft Tissue Sarcoma oTreated with Doxorubicin-Based Chemotherapy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932429/

The deck was put together to present the opportunity to big pharma and I'm sure CC is doing exactly that.

Selected for a reason:

Dr. Coughlin trained as an oncologist and immunologist at the University of Pennsylvania and her career in industry has included roles with increasing seniority at major biopharmaceutical companies including Novartis.

Her role at Novartis

Executive Director, Clinical Program Leader in Oncology

Novartis

Dec 2012 - Dec 2015 ·

The sub-study through partnership with SOFIE utilising baseline [18F]FAPI-74 PET scanning in the AVA6000 Phase 1 trial has commenced

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc. The FAP assets were originally developed at the University of Heidelberg. The agreement also includes co-exclusive rights for Novartis to develop imaging applications for these assets.

Thorn

You sound desperate.

The fact they have identified technology that will aid with precise candidate selection more or less nullifies any material risk related to future efficacy studies.

Surely you can see that this is positive?

Hopefully this will silence the trolls and we can get back to 100p in short order.

Gsa will help close the gap by COB Monday

Fancy the GAP above to close this week.

Looks like we could really pop soon.

Rapid rise to 100p+ please

Based on today's performance the 'important announcements' to be released during the preliminary next week, are likely to be quite exciting.

Does the market have wind of something?

The strength today is sustained.

Interesting start for sure. We have some buying pressure

I have heard that there will be 'important announcements'next week during the preliminary results.